Opal Wealth Advisors LLC Purchases 2,414 Shares of AstraZeneca PLC (NASDAQ:AZN)

Opal Wealth Advisors LLC boosted its position in AstraZeneca PLC (NASDAQ:AZN) by 96.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 4,916 shares of the company’s stock after purchasing an additional 2,414 shares during the period. Opal Wealth Advisors LLC’s holdings in AstraZeneca were worth $383,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Asset Dedication LLC increased its holdings in shares of AstraZeneca by 14.7% in the third quarter. Asset Dedication LLC now owns 2,923 shares of the company’s stock valued at $228,000 after purchasing an additional 374 shares during the last quarter. Braun Bostich & Associates Inc. bought a new stake in shares of AstraZeneca during the 3rd quarter worth about $206,000. Foster Victor Wealth Advisors LLC grew its stake in AstraZeneca by 13.2% in the 3rd quarter. Foster Victor Wealth Advisors LLC now owns 3,759 shares of the company’s stock valued at $291,000 after buying an additional 437 shares during the last quarter. Swedbank AB raised its holdings in AstraZeneca by 1.3% in the 3rd quarter. Swedbank AB now owns 2,705,757 shares of the company’s stock valued at $210,806,000 after acquiring an additional 35,000 shares during the period. Finally, Creative Planning lifted its position in AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after acquiring an additional 16,692 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Finally, TD Cowen lifted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

AZN stock opened at $77.85 on Wednesday. The company’s 50-day moving average price is $81.31 and its two-hundred day moving average price is $78.04. The firm has a market cap of $241.38 billion, a P/E ratio of 37.61, a P/E/G ratio of 1.44 and a beta of 0.46. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The business had revenue of $12.45 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same period last year, the firm posted $1.08 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. On average, analysts anticipate that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were issued a dividend of $0.49 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio (DPR) is currently 47.34%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.